Phase II Study of Intraperitoneal Irinotecan with Systemic Chemotherapy for Patients with Gastric Cancer Peritoneal Metastases

What this Trial Is About

Researchers are conducting a phase II study in the Netherlands to evaluate a new combination treatment for patients with gastric cancer that has spread to the peritoneum gastric peritoneal metastases. The study aims to determine if adding intraperitoneal irinotecan chemotherapy to standard systemic treatments is feasible. The study may also include additional drugs, nivolumab or trastuzumab, depending on patients biomarker results. Patients will receive intraperitoneal irinotecan through a special access port alongside standard systemic chemotherapy such as CAPOX or FOLFOX. The treatment consists of either 6 cycles of CAPOX each cycle lasting 21 days or 8 cycles of FOLFOX each cycle lasting 14 days. This combined approach is being tested at three hospitals to assess its practical use in patients. During the study, patients will be closely monitored from enrollment until they complete all chemotherapy cycles. Researchers will evaluate the feasibility of administering irinotecan directly into the peritoneum alongside systemic therapy. Participants will undergo regular assessments to track treatment adherence and safety. The total involvement duration depends on the chemotherapy regimen chosen, lasting through all treatment cycles.

INTERACT Stomach-II